Breaking News, Collaborations & Alliances

Lonza and DiNAQOR AG Enter Gene Therapy Collaboration

Lonza’s manufacturing site in Houston, TX will handle all product supply for DiNA-001.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lonza and DiNAQOR AG, a global gene therapy platform company, have formed a collaboration to advance DiNAQOR’s preclinical programs for the treatment of cardiac myosin-binding protein-C (MYBPC3) cardiomyopathies, a genetic condition that can result in heart failure.   Lonza will provide DiMAQOR preclinical, clinical and commercial production support for the company’s lead preclinical program DiNA-001, an adeno-associated virus (AAV) gene therapy program for patients with MYBPC3-linked cardiomy...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters